Bengaluru-based SigTuple has raised Rs 33 crore ($4 million) led by SIDBI Venture Capital, with participation from existing investors including Endiya Partners, and a few strategic leaders from the healthcare sector. The team will use this new capital to drive geographical expansion, expand its product portfolio and support regulatory clearances.

Since 2020, SigTuple has focused on its core product, AI100, which is now gaining significant traction in the Indian market with major diagnostics industry players as customers.

Partnering with Horiba Medical as its South Asia distribution channel, SigTuple has also expanded into Southeast Asia, the Middle East, and North Africa, and is poised to enter Europe and the Americas.

In September 2023, AI100 received US FDA 510(k) approval, making SigTuple the third company globally, and the first in India, to achieve this for AI-assisted digital hematology.

SigTuple's robust product roadmap has significant developments ahead. The company is set to launch a next-generation product that automates all manual microscopy in clinical labs, surpassing the AI100. Additionally, SigTuple is entering the point-of-care market with microfluidic technology and imaging to process essential tests in minutes, promoting decentralization and making quality diagnostics accessible.

With new funding, SigTuple is poised to design and produce innovative, high-end medical devices in India for a global audience, turning its vision into reality.